Business
Bain & Company Signage
Bain & Company’s logo (Smith Collection/Gado/Getty Images)

Consultants keep winning the AI wars

Bain is the latest consulting firm to cash in on the AI boom.

In late June, we discussed how consulting firms had quietly become the big winners of the AI boom.

Accenture generated $900 million, or an annualized $3.6 billion, in GenAI bookings in Q3, compared to OpenAIs annualized revenue of $3.4 billion at the time. Additionally, Boston Consulting Group, which had $12.3 billion in 2023 revenue, projected that 20% of its 2024 revenue and 40% of its 2026 revenue would come from AI integration projects, and IBMs consulting arm had booked a cumulative $1 billion from its AI products.

Four months later, the management consulting x artificial intelligence business pipeline remains quite robust, with The Wall Street Journal reporting that OpenAI and Bain have expanded their partnership, allowing Bain to sell industry-specific solutions built on OpenAI to clients:

At the core of the deal is a team that will build industry-specific artificial-intelligence tools for sectors including retail and life sciences, said Christophe De Vusser, worldwide managing partner and chief executive of the consulting firm. Bain is putting about 50 employees into the joint effort. OpenAI Chief Operating Officer Brad Lightcap declined to say how many OpenAI team members will be involved.

When I first wrote about Accenture's $3.6 billion generative-AI business, I found it amusing that the only company (besides OpenAI, of course), that had managed to make money on artificial intelligence was a consulting firm. However, looking at it now, these AI x consulting partnerships actually make a lot of sense.

Consulting firms, at the end of the day, are paid to help clients improve their businesses. OpenAIs models are incredible tools that can help users more effectively organize, understand, and draw conclusions from data, but these models, by default, arent fine-tuned to work with specific users data.

Yes, an individual can log on ChatGPT and use it as a research tool, but in its basic format, companies cant just seamlessly integrate ChatGPT with their private data to improve their businesses. While some companies, like fintech unicorn Ramp, have leveraged OpenAIs models to enhance their own products, other companies either dont have or dont want to use internal resources to build their own OpenAI-based tools.

Enter: consulting firms, who are, as we said, paid to help clients improve their businesses. Bain knows OpenAI can be used to improve clients businesses, OpenAI knows that enterprise clients are highly lucrative, and many enterprise clients would rather pay Bain to build their OpenAI solutions than develop them internally. Its really a win-win-win relationship for all three parties.

Shout-out to the consultants. Heads, they win; tails, they still dont lose.

More Business

See all Business
business

Hims to stop offering copy of Wegovy pill following FDA scrutiny

Hims & Hers said it has decided to stop offering its newly launched copycat version of Novo Nordisk’s Wegovy pill, after the telehealth company drew criticism from the Food and Drug Administration. 

“Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment,” Hims wrote on X.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Hims oral semaglutide

Hims, long flying under regulators’ radar, finally strikes a nerve with its Wegovy pill copy

It’s unclear if the pill Hims is selling works or if the FDA will allow it.

$1.3M

There’s still plenty of money to be made in brainrot. The top 1,000 Roblox creators earned an average of $1.3 million in 2025 — up 50% from the year prior — according to CEO Dave Baszucki on the company’s fourth-quarter earnings call.

Roblox paid out $1.5 billion to creators last year, meaning its top 1,000 creators took home about 87% of the total pool.

Like other creator economy giants, Roblox rewards its biggest creators for their contributions to user engagement. Creator-made titles like “Grow a Garden” and “Steal a Brainrot” substantially boosted playing time over the course of the year. In September, the company increased its developer exchange rate, or the ratio of in-game currency to cash payout, by 8.5%.

Texas Governor Abbott And Google Make Economic Development Announcement In Midlothian

Alphabet could buy some pretty huge businesses with the amount of money it plans to spend this year

AI outlays have gone full nut-nut. Even Google, one of the most capital-efficient businesses of all time in its heyday, is spending like there’s no tomorrow.

Tom Jones2/6/26

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.